QuidelOrtho Corporation to Report First Quarter 2024 Financial Results on May 8, 2024
QuidelOrtho Corporation to Report First Quarter 2024 Financial Results
SAN DIEGO, April 17, 2024– QuidelOrtho Corporation (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies, announced today that it will be reporting its financial results for the first quarter ended March 31, 2024. The report will be released after the market closes on Wednesday, May 8, 2024.
Following the release of the financial results, QuidelOrtho will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the company’s website at https://ir.quidelortho.com/. Presentation materials will also be available on the website at the time of the call. For those unable to access the webcast, a phone option is available by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 295379.
A replay of the conference call will be available on the “Investor Relations” page of the company’s website under the “Events & Presentations” section.
QuidelOrtho Corporation is a world leader in in vitro diagnostics, offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine. The company aims to provide fast, accurate, and reliable diagnostics to patients, clinicians, and health officials worldwide.
For more information, visit www.quidelortho.com.
Source: QuidelOrtho Corporation
Contacts:
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
[email protected]
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
[email protected]
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417178380/en/
This news story highlights the upcoming financial report of QuidelOrtho Corporation and provides details on how interested parties can access the conference call to discuss the results. It also gives an overview of the company’s focus on providing innovative diagnostic solutions globally.